Sanofi reported to be looking at an Insmed takeover
Sanofi's chief executive, Belén Garijo.
Sanofi's new chief executive Belén Garijo has said she wants to make some M&A deals, and the rumour mill is now linking the French group to a possible takeover of Insmed.
A Bloomberg report, citing anonymous sources close to the matter, says Sanofi is working with advisers to evaluate a potential acquisition of US-based Insmed, which has two approved respiratory medicines and a pipeline spanning respiratory, immunology and inflammation (I&I), and neurological/rare disease.
The sticking point for Sanofi could be Insmed's sky-high valuation, with the report suggesting the pharma group would have to pay between $35 billion and $43 billion – which would make it the largest biopharma buyout since Pfizer spent $43 billion on Seagen in 2023.
That valuation means Sanofi cannot cover the cost with cash alone, and – unless the deal could include a stock component – the pharma group would have to add to its debt level significantly. Neither company has commented on the rumour.
During Sanofi's third-quarter results presentation, Garijo said M&A and licensing deals, along with improvements in R&D productivity, will be key to preparing for the loss of market exclusivity for top-selling I&I drug Dupixent (dupilumab) in the early 2030s.
Dupixent made €5.7 billion in the third quarter, accounting for almost 40% of total group revenues, and Garijo told investors in October that the "whole organisation is focused on managing Sanofi's post-Dupixent trajectory over the next decade."
Adding Insmed would give Sanofi Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis and Arikayce (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease, which generated sales of $400 million and $124 million, respectively, in the third quarter. Insmed is projecting full-year revenues of $1.8-$1.9 billion.
Following in late-stage development is TPIP (treprostinil palmitil inhalation powder), which is in the phase 3 PALM programme spanning four progressive lung diseases: pulmonary hypertension with interstitial lung disease (PH-ILD); pulmonary arterial hypertension (PAH); progressive pulmonary fibrosis (PPF); and idiopathic pulmonary fibrosis (IPF).
Insmed has modelled peak annual sales of more than $6 billion for TPIP, which would go a long way towards offsetting the hit that Sanofi will suffer when biosimilar competition to Dupixent starts to impact sales.
Meanwhile, the deal would give Sanofi three other pipeline candidates for IPF/PPF, rheumatoid arthritis and inflammatory bowel disease, and Duchenne muscular dystrophy (DMD).
Garijo has already taken steps to prepare for Sanofi's post-Dupixent era since taking the helm in April, launching a clear-out of the company's pipeline to focus on the strongest prospects, firming up a long-running alliance with Regeneron, and handing over rights to some of its mature medicines to Cheplapharm.
